Palliative therapy for lung cancer

Seminars in Surgical Oncology

Volumn 21, Issue 2, 2003, Pages 138-147

  Bezjak, Andrea ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Chemotherapy; Lung cancer; Palliation; Radiotherapy; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MITOMYCIN C; NAVELBINE; PACLITAXEL; VINBLASTINE; VINDESINE;

AIRWAY OBSTRUCTION; BEAM THERAPY; BONE METASTASIS; BRACHYTHERAPY; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; HUMAN; LEUKOPENIA; LUNG CANCER; NEODYMIUM LASER; NEUROTOXICITY; PERICARDIAL EFFUSION; PHOTODYNAMIC THERAPY; PLEURA EFFUSION; PLEURODESIS; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; REVIEW; STENT; SYMPTOM; THORACOCENTESIS; TREATMENT OUTCOME; VOMITING;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; PALLIATIVE CARE; QUALITY OF LIFE;

EID: 0141997066     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/ssu.10031     Document Type: Review

References (57)

1. Ruckdeschel JC, Piantadosi S: Quality of life in lung cancer surgical adjuvant trials. Chest 1994;106:324S-328S.
2. Kaasa S, Mastekaasa A, Lund E: Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease. The importance of patients' subjective experience of disease and psychosocial well-being. Radiother Oncol 1989;15:235-242.
3. Ganz PA, Lee JJ, Siau J: Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer 1991;67:3131-3135.
4. Regan J, Yarnold J, Jones PW, Cooke NT: Palliation and life quality in lung cancer; how good are clinicians at judging treatment outcome? Br J Cancer 1991;64:396-400.
5. Stephens RJ, Hopwood P, Girling DJ, Machin D: Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res 1997;6:225-236.
6. Stephens RJ, Hopwood P, Girling DJ: Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer 1999;79:538-544.
7. Anderson H, Hopwood P, Stephens RJ, et al: Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-small cell lung cancer. Br J Cancer 2000;83:447-453.
8. Hopwood P, Stephens RJ: Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party. Br J Cancer 1995;71:633-636.
9. Simpson JR, Francis ME, Perez-Tamayo R, et al: Palliative radiotherapy for inoperable carcinoma of the lung: final report of a RTOG multi-institutional trial. Int J Radiat Oncol Biol Phys 1985;11:751-758.
10. Teo P, Tai TH, Choy D, Tsui KH: A randomized study on palliative radiation therapy for inoperable non small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1988;14:867-871.
11. Abratt RP, Shepherd LJ, Salton DG: Palliative radiation for stage 3 non-small cell lung cancer-a prospective study of two moderately high dose regimens. Lung Cancer 1995;13:137-143.
12. Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomized trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer 1991;63:265-270.
13. A Medical Research Council (MRC) randomized trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party. Br J Cancer 1992;65:934-941.
14. Macbeth FR, Bolger JJ, Hopwood P, et al: Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) 1996;8:167-175.
15. Ball D, Smith J, Bishop J, et al: A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small-cell lung cancer. Br J Cancer 1997;75:690-697.
16. Rees GJ, Devrell CE, Barley VL, Newman HF: Palliative radiotherapy for lung cancer: two versus five fractions. Clin Oncol (R Coll Radiol) 1997;9:90-95.
17. Nestle U, Nieder C, Walter K, et al: A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs. conventionally fractionated 60 GY: results of a randomized equivalence study. Int J Radiat Oncol Biol Phys 2000;48:95-103.
18. Bezjak A, Dixon P, Brundage M, et al: Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys 2002;54:719-728.
19. Macbeth F, Toy E, Coles B, et al: Palliative radiotherapy regimens for non-small cell lung cancer (Cochrane Review). Cochrane Database Syst Rev 2001;3:CD002143.
20. Falk SJ, Girling DJ, White RJ, et al: Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomized controlled trial. BMJ 2002;325(7362):465.
21. Barton R, Kirkbride P: Special techniques in palliative radiation oncology. J Palliat Med 2000;3:75-83.
22. Gollins SW, Burt PA, Barber PV, Stout R: Long-term survival and symptom palliation in small primary bronchial carcinomas following treatment with intraluminal radiotherapy alone. Clin Oncol (R Coll Radiol) 1996;8:239-246.
23. Stout R, Barber P, Burt P, et al: Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) vs. external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer. Radiother Oncol 2000;56:323-327.
24. Roszkowski K, Pluzanska A, Krzakowski M, et al: A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000;27:145-157.
25. Gridelli C: The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Oncologist 2001;6:4-7.
26. Gridelli C, Perrone F, Gallo C, et al: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372.
27. Gridelli C, Gallo C, Shepherd F, et al: Gemcitabine plus Vinorelbine Compared with Cisplatin plus Vinorelbine or Cisplatin plus Gemcitabine for advanced non-small cell lung cancer: A phase III trial of the Italian GEMVIN investigation and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21(16).
28. Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6:633-641.
29. Helsing M, Bergman B, Thaning L, Hero U: Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group. Eur J Cancer 1998;34:1036-1044.
30. Cullen MH, Billingham LJ, Woodroffe CM, et al: Mitomycin, ifosfamide, and cisplatin in unresectable nonsmall-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999;17:3188-3194.
31. Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J: Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999;24:17-24.
32. Ranson M, Davidson N, Nicolson M, et al: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1074-1080.
33. Lopez PG, Stewart DJ, Newman TE, Evans WK: Chemotherapy in stage IV (metastatic) non-small-cell lung cancer. Provincial Lung Disease Site Group. Cancer Prev Control 1997;1:18-27.
34. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
35. Fossella FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000;18:2354-2362.
36. Lee RB: Surgical palliation of airway obstruction resulting from lung cancer. Semin Surg Oncol 2000;18:173-182.
37. Moghissi K, Bond MG, Sambrook RJ, et al: Treatment of endotracheal or endobronchial obstruction by non-small cell lung cancer: lack of patients in an MRC randomized trial leaves key questions unanswered. Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) 1999;11:179-183.
38. Wieman TJ, Diaz-Jimenez JP, Moghissi K, et al: Photodynamic Therapy Lung Cancer Study Group, Louisville KY, Barcelona Spain. Photodynamic therapy (PDT) with photofrin® is effective in the palliation of obstructive endobronchial lung cancer: results of two randomized trials [Abstract]. Proc Am Soc Clin Oncol 1998;17:464a:1782.
39. Lam S, Grafton C, Coy P, et al: Combined photodynamic therapy (PDT) using photofrin* and radiotherapy (XRT) versus radiotherapy alone in patients with inoperable obstructive non-small cell bronchogenic carcinoma. SPIE 1991;1616:20-28.
40. Kirkbride P, Mackillop WJ, Priestman TJ, et al: The role of palliative radiotherapy for bone metastases. Can J Oncol 1996;6:33-38.
41. Wu JS, Bezjak A, Chow E, Kirkbride P: Primary treatment endpoint following palliative radiotherapy for painful bone metastases: need for a consensus definition? Clin Oncol (R Coll Radiol) 2002;14:70-77.
42. Ratanatharathorn V, Powers WE, Moss WT, Perez CA: Bone metastasis: review and critical analysis of random allocation trials of local field treatment. Int J Radiat Oncol Biol Phys 1999;44:1-18.
43. McQuay HJ, Collins SL, Carroll D, Moore RA: Radiotherapy for the palliation of painful bone metastases. Cochrane Database Syst Rev 2000:CD001793.
44. Wu J, Wong R, Johnston M, et al: Meta analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003;55:594-605.
45. Chow E, Wu JS, Hoskin P, et al: International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 2002;64:275-280.
46. Patchell RA, Tibbs PA, Walsh JW, et al: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500.
47. Mintz AH, Kestle J, Rathbone MP, et al: A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996;78:1470-1476.
48. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al: Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993;33:583v590.
49. Kondziolka D, Patel A, Lunsford LD, et al: Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999;45:427-434.
50. Bezjak A, Adam J, Barton R, et al: Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 2002;38:487-496.
51. Borgelt B, Gelber R, Larson M, et al: Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981;7:1633-1638.
52. Borgelt B, Gelber R, Kramer S, et al: The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980;6:1-9.
53. Haie-Meder C, Pellae-Cosset B, Laplanche A, et al: Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases. Radiother Oncol 1993;26:111-116.
54. Kurtz JM, Gelber R, Brady LW, et al: The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981;7:891-895.
55. Priestman TJ, Dunn J, Brada M, et al: Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol (R Coll Radiol) 1996;8:308-315.
56. Gaspar L, Scott C, Rotman M, et al: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745-751.
57. Gaspar LE, Scott C, Murray K, Curran W: Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 2000;47:1001-1006.